Javascript must be enabled to continue!
Superiority of sirolimus eluting stent compared with intracoronary β radiation for treatment of in-stent restenosis: a matched comparison
View through CrossRef
Objective: To compare acute and follow up clinical and angiographic results after treatment of in-stent restenosis (ISR) by sirolimus eluting stents (SES) with results obtained after intracoronary radiation therapy (IRT).
Design: Matched pair analysis.
Methods: 62 consecutive ISR lesions (< 30 mm lesion length, reference diameter < 3.5 mm) in 62 patients were treated with SES. From a database of 174 lesions (n = 141 patients) treated for ISR by intracoronary β radiation, 62 lesions (62 patients) were pair matched with the SES group for diabetes mellitus, lesion length, vessel size, and pattern of ISR. Six month angiographic and 12 month clinical follow up results were obtained.
Results: Baseline clinical and angiographic characteristics were similar between the groups (not significant). SES implantation resulted in significantly lower postprocedural in-lesion diameter stenosis than did IRT (mean (SD) 14.2 (9.5)% v 21.1 (10.6)%, p = 0.001), significantly higher minimum lumen diameter at follow up (1.91 (0.58) v 1.55 (0.72) mm, p = 0.005), and a higher net gain (1.16 (0.55) v 0.77 (0.70) mm, p = 0.002). Angiographic binary in-lesion restenosis rate at six months was 11% in the SES group and 29% in the IRT group (p = 0.046). In 16 ISR lesions SES were used after failed IRT and in 46 lesions for first time ISR. In-lesion late loss was higher after use of SES for failed IRT than after use of SES for first time ISR (0.61 (0.67) mm v 0.24 (0.41) mm, p = 0.018). In a multivariate analysis prior failed IRT was the only independent predictor for recurrent restenosis after SES for ISR (p = 0.052, odds ratio 5.8). Six patients (10%) in the SES group and 17 patients (27%) in the IRT group underwent target lesion revascularisation during the 12 months of follow up (p = 0.022).
Conclusions: In this non-randomised matched cohort SES achieved acute and follow up results superior to IRT for treatment of ISR even if cases of failed IRT are included. Failed IRT is a predictor of impaired SES effectiveness.
Title: Superiority of sirolimus eluting stent compared with intracoronary β radiation for treatment of in-stent restenosis: a matched comparison
Description:
Objective: To compare acute and follow up clinical and angiographic results after treatment of in-stent restenosis (ISR) by sirolimus eluting stents (SES) with results obtained after intracoronary radiation therapy (IRT).
Design: Matched pair analysis.
Methods: 62 consecutive ISR lesions (< 30 mm lesion length, reference diameter < 3.
5 mm) in 62 patients were treated with SES.
From a database of 174 lesions (n = 141 patients) treated for ISR by intracoronary β radiation, 62 lesions (62 patients) were pair matched with the SES group for diabetes mellitus, lesion length, vessel size, and pattern of ISR.
Six month angiographic and 12 month clinical follow up results were obtained.
Results: Baseline clinical and angiographic characteristics were similar between the groups (not significant).
SES implantation resulted in significantly lower postprocedural in-lesion diameter stenosis than did IRT (mean (SD) 14.
2 (9.
5)% v 21.
1 (10.
6)%, p = 0.
001), significantly higher minimum lumen diameter at follow up (1.
91 (0.
58) v 1.
55 (0.
72) mm, p = 0.
005), and a higher net gain (1.
16 (0.
55) v 0.
77 (0.
70) mm, p = 0.
002).
Angiographic binary in-lesion restenosis rate at six months was 11% in the SES group and 29% in the IRT group (p = 0.
046).
In 16 ISR lesions SES were used after failed IRT and in 46 lesions for first time ISR.
In-lesion late loss was higher after use of SES for failed IRT than after use of SES for first time ISR (0.
61 (0.
67) mm v 0.
24 (0.
41) mm, p = 0.
018).
In a multivariate analysis prior failed IRT was the only independent predictor for recurrent restenosis after SES for ISR (p = 0.
052, odds ratio 5.
8).
Six patients (10%) in the SES group and 17 patients (27%) in the IRT group underwent target lesion revascularisation during the 12 months of follow up (p = 0.
022).
Conclusions: In this non-randomised matched cohort SES achieved acute and follow up results superior to IRT for treatment of ISR even if cases of failed IRT are included.
Failed IRT is a predictor of impaired SES effectiveness.
Related Results
Predictors of insistent restenosis in patients undergoing percutaneous intervention
Predictors of insistent restenosis in patients undergoing percutaneous intervention
Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. The first percutaneous coronary intervention was performed by Andreas Gruntzig on Septemb...
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Two hundred forty-six patients with 252 bifurcation lesions were enrolled into a prospective, nonrandomized study to use paclitaxel-eluting or sirolimus-eluting stent for crush ste...
Effects of PIP targeting LOX-1 eluting stents on in-stent restenosis and re-endothelialisation in rat abdominal aorta stenting models
Effects of PIP targeting LOX-1 eluting stents on in-stent restenosis and re-endothelialisation in rat abdominal aorta stenting models
Background and Objectives
Pyrrole-Imidazole polyamide (PIP) is a novel gene silencer that can be readily designed and synthesised to target any gene. Contrary to ...
Incidence and Management of In-Stent Restenosis in Patients with Drug-Eluting Stents
Incidence and Management of In-Stent Restenosis in Patients with Drug-Eluting Stents
Introduction: The most prevalent complication of cardiac intervention is restenosis. After the BMS period, drug-eluting stents (DES) are the most suitable choice for stenosis treat...
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
BACKGROUND:
Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbrevi...
Sirolimus PK trial: A pharmacokinetic study of the sirolimus‐eluting Bx Velocity stent in patients with de novo coronary lesions
Sirolimus PK trial: A pharmacokinetic study of the sirolimus‐eluting Bx Velocity stent in patients with de novo coronary lesions
AbstractThis study was conducted to assess the systemic drug release and distribution of sirolimus‐eluting stents. Early results with sirolimus‐eluting stents have demonstrated a f...
Six-Month Angiographic Outcome After Successful Repeat Percutaneous Intervention for In-Stent Restenosis
Six-Month Angiographic Outcome After Successful Repeat Percutaneous Intervention for In-Stent Restenosis
Background
—In-stent restenosis is an increasing clinical problem. Discordant results have been published regarding the risk of recurrent restenosis after repeat angiop...
CLINICAL APPLICATION OF DOMESTIC LONG BIODEGRADABLE POLYMER COATED SIROLIMUS ELUTING STENTS FOR TREATMENT OF LONG CORONARY ARTERY LESIONS
CLINICAL APPLICATION OF DOMESTIC LONG BIODEGRADABLE POLYMER COATED SIROLIMUS ELUTING STENTS FOR TREATMENT OF LONG CORONARY ARTERY LESIONS
Objectives
To evaluate the efficacy and safety of domestic long biodegradable polymer coated sirolimus eluting stents (Excel stent, Shandong JW) for treatment of ...

